Comparison of photodynamic therapy and ranibizumab therapy for the treatment of polypoidal choroidal vasculopathy

Multicenter randomized comparative study of photodynamic therapy and ranibizumab therapy for the visual acuity improvement in patient with polypoidal choroidal vasculopathy. - LAPTOP (comparison of Lucentis And Photodynamic Therapy On Pcv)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1090220028

Enrollment

124

Registered

2009-06-22

Start date

2009-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy

Interventions

Intervention type:DRUG,PROCEDURE Name of intervention:intravitreal injection of ranibizumab Dose form / Japanese Medical Device Nomenclature:INJECTION Route of administration / Site of application:OPH

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Cases with PCV, with or without type II CNV, according to diagnostic criteria by Japanese PCV society. 2 No prior treatment 3 Best corrected visual acuity < 0.6 4 Patients with written informed consent.

Exclusion criteria

Exclusion criteria: 1 Greatest linear dimension >= 5400 micrometer 2 Myopia = 26.5mm

Design outcomes

Primary

Measure	Time frame
The proportion of subjects who gain 0.2 or more best corrected visual acuity at 12 months compared to baseline, based on LogMAR.	—

Secondary

Measure	Time frame
drop-out rate, mean visual acuity, required number of treatment.	—

Countries

Japan

Contacts

Public ContactNoriko Miyamoto

Kobe city medical center general hospital

miyafrac@kcho.jp+81-78-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026